The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of prolapse is listed in the xience sierra everolimus eluting coronary stent systems instructions for use (ifu) as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
Patient id (b)(6).It was reported that the procedure was performed to treat a lesion in the proximal right coronary artery (rca).A 3.5 x 23 mm xience sierra stent was implanted at the target lesion, resulting in plaque shift and residual stenosis, so a second unplanned stent, a 3.5 x 12 mm xience sierra, was implanted, overlapping the 3.5 x 23 mm xience sierra stent.Post procedure, residual stenosis was 0% and the event was resolved.No additional information was provided.
|